The trial will assess the therapy’s pharmacokinetics, pharmacodynamics and safety, as well as its impact on disease activity.

Cambridge, Massachusetts Saturday, April 19, 2025, 15:00 Hrs [IST] ...

This subcutaneous CD19/CD3-directed bispecific-TCE (BiTE) demonstrated deep B-cell depletion and a favourable safety profile with weekly injections in Phase 1 trials for non-Hodgkin’s lymphoma ...

Boehringer Ingelheim has joined the surge of companies entering the B-cell depletion space. But while its peers have largely ...

Bargou et al. assessed the efficacy of blinatumomab—an antibody with dual specificity for CD19 and CD3 antigens—in patients with non-Hodgkin lymphoma who relapsed after standard treatments.

The deal centres around TNB-486, a bispecific CD19 and CD3 T-cell engager in phase 1 testing in patients with relapsed and refractory B-cell non-Hodgkin lymphoma (NHL) who have received two or ...

Cullinan Therapeutics rebranded from oncology to immunology+oncology, focusing on CD19 TCEs for autoimmune diseases. Check ...